PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics

PTC Therapeutics, Inc. (PTCT)

Today's Latest Price: $63.99 USD

0.46 (0.72%)

Updated Nov 27 1:00pm

Add PTCT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

PTCT Stock Summary

  • Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 17.98% of US stocks have a lower such ratio.
  • With a price/sales ratio of 12.18, Ptc Therapeutics Inc has a higher such ratio than 87.38% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Ptc Therapeutics Inc is reporting a growth rate of 74.92%; that's higher than 85.56% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ptc Therapeutics Inc are FOLD, BCRX, CLSN, LOGC, and DCPH.
  • PTCT's SEC filings can be seen here. And to visit Ptc Therapeutics Inc's official web site, go to

PTCT Stock Price Chart Interactive Chart >

Price chart for PTCT

PTCT Price/Volume Stats

Current price $63.99 52-week high $64.62
Prev. close $63.53 52-week low $30.79
Day low $63.27 Volume 245,400
Day high $64.61 Avg. volume 734,630
50-day MA $54.33 Dividend yield N/A
200-day MA $50.47 Market Cap 4.37B

PTC Therapeutics, Inc. (PTCT) Company Bio

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.

PTCT Latest News Stream

Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream

Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

Roche and PTC's risdiplam shows durable effect in infants with spinal muscular atrophy

PTC Therapeutics (PTCT) and exclusive licensee Genentech, a unit of Roche (RHHBY), announce two-year data from Part 1 of the pivotal Phase 2/3 FIREFISH study evaluating Evrysdi (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy ((SMA)). Infants treated receiving the therapeutic dose of Evrysdi continued...

Seeking Alpha | September 28, 2020

PTC Therapeutics earns $20M milestone from Roche on sale of risdiplam in U.S.

PTC Therapeutics (PTCT) has received a $20M milestone payment from Roche (RHHBY), triggered by the first commercial sale of Evrysdi (risdiplam) in the U.S., under its License and Collaboration Agreement.Risdiplam is a survival motor neuron-2 (SMN2) splicing modifier designed to increase and sustain SMN protein levels throughout the central nervous system and...

Seeking Alpha | August 26, 2020

Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval

The U.S. Food and Drug Administration on Friday approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc for spinal muscular atrophy in adults and children two months and above.

Reuters | August 7, 2020

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on Wednesday, August 5, 2020 at 4:30 p.m. (ET) after the closing of the market.

Yahoo | July 22, 2020

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo 22.61%
3-mo 29.47%
6-mo 25.59%
1-year 36.26%
3-year 301.19%
5-year 117.65%
YTD 33.23%
2019 39.95%
2018 105.76%
2017 52.89%
2016 -66.33%
2015 -37.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9113 seconds.